peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

GIP/GLP-1 receptor agonist · 39 amino acids

Tirzepatide

/tir-ZEP-a-tide/FDA-approved ingredient
Loading scientific anatomy…
Interactive anatomy · drag to rotate

02 · Consumer names

One ingredient.
Distinct products.

01

Mounjaro

Weekly subcutaneous injection

Type 2 diabetes.

Find official label ↗
02

Zepbound

Weekly subcutaneous injection

Chronic weight management and product-specific obstructive sleep apnea use.

Find official label ↗

Product names are not synonyms for one another. Route, strength, indication, and instructions can differ. Compare with primary label

03 · Mechanism + use

What the molecule does,
and where the label stops.

What it does
Agonism at GIP and GLP-1 receptors increases glucose-dependent insulin secretion, reduces glucagon, slows gastric emptying, and reduces food intake.Mechanism source
Labeled-use boundary
Mounjaro and Zepbound share an ingredient but not a single indication or dosing record.Primary label

04 · Labeled safety

Risk belongs
beside benefit.

Boxed warning

Labels warn about thyroid C-cell tumors observed in rats; human relevance is unknown.Open boxed warning

Who should avoid it

  • Personal or family history of medullary thyroid carcinoma
  • MEN 2
  • Serious hypersensitivity to tirzepatide
Contraindications

More common effects

  • Nausea
  • Diarrhea
  • Decreased appetite
  • Vomiting
  • Constipation
  • Dyspepsia
  • Abdominal pain
Adverse reactions

Important serious risks

  • Acute pancreatitis
  • Hypoglycemia with insulin or secretagogues
  • Acute kidney injury from dehydration
  • Gallbladder disease
  • Severe gastrointestinal reactions
Warnings

This is a structured label summary, not a complete prescribing-information substitute and not a personalized risk estimate.

05 · Evidence interpretation

Claims with
their edges visible.

01

Dual-receptor pharmacology

The molecule combines GIP and GLP-1 receptor agonism in one long-acting peptide.

Supporting source
Evidence form
Mechanistic and clinical pharmacology
Keep in view
Mechanism alone does not predict individual benefit.
02

Glycemic and weight outcomes

Randomized SURPASS and SURMOUNT programs measured distinct endpoints in distinct populations.

Supporting source
Evidence form
Large randomized programs
Keep in view
Cross-trial comparisons can be misleading.
03

Product-specific safety

Warnings and common reactions are synthesized in each approved product label.

Supporting source
Evidence form
Regulatory synthesis
Keep in view
Label rates depend on dose, trial, and comparator.

06 · Research universe

Reviewed anchors.
Live indexes.

The regulatory label anchors approved use and safety. PubMed and ClinicalTrials.gov expose the broader, continuously changing research universe without pretending every result has been reviewed.

  1. 01Regulatory label
    Mounjaro prescribing information

    Current DailyMed label for tirzepatide marketed as Mounjaro.

    Open source ↗
  2. 02Literature index
    Every PubMed result for tirzepatide

    Live National Library of Medicine literature search; results are not pre-screened or deduplicated.

    Open source ↗
  3. 03Trial registry
    Every registered study for tirzepatide

    Live ClinicalTrials.gov search, including completed, active, and historical records.

    Open source ↗
  4. 04Chemical record
    tirzepatide chemical record

    PubChem compound search from the National Library of Medicine.

    Open source ↗